Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial

Günter U Höglinger, Irene Litvan, Nuno Mendonca, Deli Wang, Hui Zheng, Beatrice Rendenbach-Mueller, Hoi-Kei Lon, Ziyi Jin, Nahome Fisseha, Kumar Budur, Michael Gold, Davis Ryman, Hana Florian, Anwar Ahmed, Ikuko Aiba, Alberto Albanese, Kelly Bertram, Yvette Bordelon, James Bower, Jared Brosch, Daniel Claassen, Carlo Colosimo, Jean-Christophe Corvol, Paola Cudia, Antonio Daniele, Luc Defebvre, Erika Driver-Dunckley, Antoine Duquette, Roberto Eleopra, Alexandre Eusebio, Victor Fung, David Geldmacher, Lawrence Golbe, Francisco Grandas, Deborah Hall, Taku Hatano, Lawrence Honig, Jennifer Hui, Diana Kerwin, Akio Kikuchi, Thomas Kimber, Takashi Kimura, Rajeev Kumar, Peter Ljubenkov, Stefan Lorenzl, Albert Ludolph, Zoltan Mari, Nikolaus McFarland, Wassilios Meissner, Pablo Mir Rivera, Hidek Mochizuki, John Morgan, Renato Munhoz, Noriko Nishikawa, John O`Sullivan, Tomoko Oeda, Hideki Oizumi, Osamu Onodera, Fabienne Ory-Magne, Elizabeth Peckham, Ronald Postuma, Aldo Quattrone, Joseph Quinn, Stefano Ruggieri, Justyna Sarna, Paul E Schulz, John Slevin, Michele Tagliati, Daryl Wile, Zbigniew Wszolek, Tao Xie, Theresa Zesiewicz
The Lancet Neurology. 2021-03-01; 20(3): 182-192
DOI: 10.1016/S1474-4422(20)30489-0

---